Nicotine Replacement Therapy Agent - Lozenges — Competitive Intelligence Brief

Nicotine Replacement Therapy Agent - Lozenges (Nicotine Replacement Therapy Agent - Lozenges) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy. Area: Addiction.

phase 3 Nicotine replacement therapy Nicotinic acetylcholine receptors Addiction Small molecule

Target snapshot

Nicotine Replacement Therapy Agent - Lozenges (Nicotine Replacement Therapy Agent - Lozenges) — NYU Langone Health. Lozenges release nicotine into the bloodstream to help manage withdrawal symptoms and cravings.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine Replacement Therapy Agent - Lozenges TARGET	Nicotine Replacement Therapy Agent - Lozenges	NYU Langone Health	phase 3	Nicotine replacement therapy	Nicotinic acetylcholine receptors
nicotine patch plus nicotine gum/lozenge	nicotine patch plus nicotine gum/lozenge	University of Minnesota	marketed	Nicotine replacement therapy (NRT) combination	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine polacrilex lozenge	Nicotine polacrilex lozenge	University of Maryland, Baltimore	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Naltrexone Tablet and Nicotine Patch	Naltrexone Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Opioid antagonist + nicotine replacement therapy combination	Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine)
Standard Duration Combination NRT	Standard Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy combination	Nicotinic acetylcholine receptors
NicoDerm CQ Patch	NicoDerm CQ Patch	Chrono Therapeutics, Inc.	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Iowa City Veterans Affairs Medical Center · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. University of Hawaii · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Vermont · 1 drug in this class
9. Ottawa Heart Institute Research Corporation · 1 drug in this class